Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23377566 | 0.85 | CHRM2 (0.47) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL23633778 | 0.84 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL7958092 | 0.82 | CHRM2 (0.43) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL21761369 | 0.82 | CHRM2 (0.43) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL25299658 | 0.80 | NR1H2 (0.39) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL527701 | 0.80 | TSHR (0.56) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL271429 | 0.80 | TSHR (0.56) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL344752 | 0.80 | TSHR (0.56) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL24751970 | 0.80 | CHRM2 (0.42) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL254562 | 0.80 | CHRM2 (0.40) | NR1H2CHRM2CHRM1CHRM3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | AMMENN ET AL, JOCHEN | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | MC1R, MC4R, MC5R | NR1H2 1224/4885CHRM2 1230/4885CHRM1 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.